menquadfi (meningococcal polysaccharide [serogroups a
menquadfi (meningococcal polysaccharide [serogroups a: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Lead developer: Sanofi (SNY)
Development Pipeline (1)
| Company | Phase |
|---|---|
| Sanofi (SNY) | Phase 3 |
Clinical Trials (1)
A Phase 3, Modified-double Blind, Multi-center Study of the Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Infants and Toddlers (2 to 23 Months of Age) in China
Frequently asked questions
Who is developing menquadfi (meningococcal polysaccharide [serogroups a?
menquadfi (meningococcal polysaccharide [serogroups a is being developed by Sanofi.
How many clinical trials involve menquadfi (meningococcal polysaccharide [serogroups a?
BioSniper tracks 1 clinical trial involving menquadfi (meningococcal polysaccharide [serogroups a.
Analyze Sanofi & menquadfi (meningococcal polysaccharide [serogroups a with AI
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
- 200 free AI credits / month to run live multi-agent analysis
- Watchlist, catalyst alerts & the biotech event calendar
- Full pipeline, financials & FDA data on every company